224 related articles for article (PubMed ID: 19276320)
1. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
Baek HM; Chen JH; Nie K; Yu HJ; Bahri S; Mehta RS; Nalcioglu O; Su MY
Radiology; 2009 Jun; 251(3):653-62. PubMed ID: 19276320
[TBL] [Abstract][Full Text] [Related]
2. Predicting Neoadjuvant Chemotherapy in Nonconcentric Shrinkage Pattern of Breast Cancer Using 1H-Magnetic Resonance Spectroscopic Imaging.
Zhou J; Qiao PG; Zhang HT; Li GJ; Jiang ZF
J Comput Assist Tomogr; 2018; 42(1):12-18. PubMed ID: 28708720
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
[TBL] [Abstract][Full Text] [Related]
4. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.
Shin HJ; Baek HM; Ahn JH; Baek S; Kim H; Cha JH; Kim HH
NMR Biomed; 2012 Dec; 25(12):1349-59. PubMed ID: 22566277
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Zhu Q; DeFusco PA; Ricci A; Cronin EB; Hegde PU; Kane M; Tavakoli B; Xu Y; Hart J; Tannenbaum SH
Radiology; 2013 Feb; 266(2):433-42. PubMed ID: 23264349
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
[TBL] [Abstract][Full Text] [Related]
8. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation.
Chen JH; Nie K; Bahri S; Hsu CC; Hsu FT; Shih HN; Lin M; Nalcioglu O; Su MY
Radiology; 2010 Apr; 255(1):44-52. PubMed ID: 20308443
[TBL] [Abstract][Full Text] [Related]
9. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
[TBL] [Abstract][Full Text] [Related]
10. Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status.
Drisis S; Flamen P; Ignatiadis M; Metens T; Chao SL; Chintinne M; Lemort M
J Magn Reson Imaging; 2018 Oct; 48(4):982-993. PubMed ID: 29659077
[TBL] [Abstract][Full Text] [Related]
11. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
12. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
15. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V
Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257
[TBL] [Abstract][Full Text] [Related]
16. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
18. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
19. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
[TBL] [Abstract][Full Text] [Related]
20. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
